{
  "nctId": "NCT03082963",
  "briefTitle": "Mapping Electrogram Morphology Recurrence for Atrial Fibrillation Ablation",
  "officialTitle": "Mapping Electrogram Morphology Recurrence for Atrial Fibrillation Ablation",
  "protocolDocument": {
    "nctId": "NCT03082963",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2019-11-19",
    "uploadDate": "2023-06-13T10:43",
    "size": 249185,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03082963/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 10,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2017-04-04",
    "completionDate": "2022-06-18",
    "primaryCompletionDate": "2022-06-18",
    "firstSubmitDate": "2017-02-27",
    "firstPostDate": "2017-03-17"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Male and female at least 21 years of age\n* persistent Afib with one prior failed ablation for persistent or long standing persistent Afib\n\nExclusion Criteria:\n\n* Inability to sign consent\n* Patients with a life expectancy less than one (1) year\n* Patients with chronic kidney disease with sufficiently low GFR that precludes either CT angiogram of the heart or contrast MRI study\n* Pregnant women and women that are breast feeding\n* Patients with multiple (2 or more) prior failed ablations\n* Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "21 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Real-time Electrogram Morphology Recurrence (EMR) Mapping Feasibility",
        "description": "As measured by number of patients where real-time EMR mapping is completed.",
        "timeFrame": "2 hours"
      }
    ],
    "secondary": [
      {
        "measure": "Ablation Acute Effects",
        "description": "ablation based on EMR map as measured by number of participants that terminate atrial fibrillation.",
        "timeFrame": "2 hours"
      },
      {
        "measure": "Number of Participants With Treatment Emergent Adverse Events",
        "description": "Number of participants with treatment emergent adverse events will be measured by the type of adverse event, severity, and whether the AE/SAE is related to the mapping",
        "timeFrame": "30 days"
      },
      {
        "measure": "Ablation Acute Effects",
        "description": "ablation based on EMR map as measured by number of participants that slow atrial fibrillation cycle length by at least 15%.",
        "timeFrame": "2 hours"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 3,
      "otherCount": 0,
      "totalCount": 4
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 29,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-21T22:34:14.591Z",
  "dataSource": "ClinicalTrials.gov API v2 - Mass Collection"
}